Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function.
about
FATP1 is an insulin-sensitive fatty acid transporter involved in diet-induced obesity.Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.Metabolic Remodeling in Diabetic Cardiomyopathy.Mechanisms regulating repression of haptoglobin production by peroxisome proliferator-activated receptor-gamma ligands in adipocytes.Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart.Cardiac remodeling in obesity.Sinoatrial node dysfunction induces cardiac arrhythmias in diabetic mice.Speckle tracking echocardiography in the diagnosis of early left ventricular systolic dysfunction in type II diabetic mice.Fatty acid (FFA) transport in cardiomyocytes revealed by imaging unbound FFA is mediated by an FFA pump modulated by the CD36 protein.Targeting metabolic disturbance in the diabetic heart.Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention.Obesity-associated improvements in metabolic profile through expansion of adipose tissue.PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation.C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists.Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization.Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure.Sex, sex steroids, and diabetic cardiomyopathy: making the case for experimental focus.Increased expression of the tail-anchored membrane protein SLMAP in adipose tissue from type 2 Tally Ho diabetic mice.Maternal hyperglycemia leads to fetal cardiac hyperplasia and dysfunction in a rat model.Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats.Myocardial metabolism of triacylglycerol-rich lipoproteins in type 2 diabetes.ErbB receptors protect the perfused heart against injury induced by epinephrine combined with low-flow ischemia.Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP.Cardiac glycogen accumulation after dexamethasone is regulated by AMPK.Perfused hearts from Type 2 diabetic (db/db) mice show metabolic responsiveness to insulin.PPAR-gamma agonists decrease hyperhomcysteinemia and cardiac dysfunction: new hope for ailing diabetic hearts?Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse.
P2860
Q28588041-0A428278-6B69-467A-8DCA-8A54724D6CACQ30353176-5F07E888-A649-424F-A3AC-A1816C7B46C0Q33354126-DFF5078A-766A-4849-A10E-BC23CEF423D2Q33623469-08BD9D09-5F48-4A01-81DA-121AF46B7B18Q33634332-EED7F5C8-1319-4ABA-A4B2-4A166DA4AD75Q33819755-659DA53B-8C55-4762-A7CF-D67C039A8E9FQ34043589-C8AB7C55-B772-438E-B4DC-1C19BDCC882FQ34108808-0DA7890A-9C09-4871-AB0A-729E729712FCQ34340227-6F7219ED-3684-42FD-9389-071968240098Q34575762-78523958-BBEB-4A0B-98E6-4955F64862BCQ35084845-D2F2FC06-64A2-49DD-970F-07D7F8A2FFB0Q35856946-CA261420-A18E-4817-8430-2E39F3D24F4BQ35945161-8058C341-76FA-464B-BD79-18C2725A5AFEQ36807667-00F9B64F-A037-45D5-A6E5-6B618C99731BQ37302225-EDFA2BFF-FA3C-4EEE-88D9-49F7248B1552Q37681949-4C1070FC-594B-438B-B295-BADCED59F662Q37704721-669BC0D4-DE82-446F-9F53-345E87B83B65Q38045551-07E557DD-A286-40DB-8A0F-E304176CDC63Q39398383-681F552D-86B4-4B23-80D5-FCF74F42D00FQ41840285-C33EDE04-0640-40FE-BA7A-C219483BB936Q44766441-5F3522C0-CE82-4BE1-BDBC-B47DB27C3D67Q45199020-2D8558F2-1339-4EFA-88EA-5486DD25CC91Q46015949-87195C74-3736-4E1D-BEF9-716A7918C48FQ46049361-56757D51-9E0A-4351-A298-75DBBD39FE60Q46375366-97939078-59FE-4095-95AF-BBB423611315Q46403678-DFF41E54-647C-43BD-A11B-3066AD8F07ADQ46835029-5256BC1E-E082-43E2-8CC5-B2FDABB6585EQ47598566-31331A06-2238-4081-8FEF-F7DA52469416Q51775769-BF5FDEB1-C721-4E8D-B0C6-97E9B7A5F494
P2860
Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Treatment of type 2 diabetic d ...... but not contractile function.
@en
Treatment of type 2 diabetic d ...... but not contractile function.
@nl
type
label
Treatment of type 2 diabetic d ...... but not contractile function.
@en
Treatment of type 2 diabetic d ...... but not contractile function.
@nl
prefLabel
Treatment of type 2 diabetic d ...... but not contractile function.
@en
Treatment of type 2 diabetic d ...... but not contractile function.
@nl
P2093
P2860
P1476
Treatment of type 2 diabetic d ...... but not contractile function.
@en
P2093
Andrew N Carley
David L Severson
Ellen Aasum
Joel P Berger
Lisa M Semeniuk
Terje S Larsen
Yakhin Shimoni
P2860
P304
P356
10.1152/AJPENDO.00329.2003
P577
2003-11-04T00:00:00Z